Detection and Localization of Carcinoma Using High Resolution Transrectal Imaging - Proof of Concept Study
An exploratory, feasibility and proof-of-concept study to evaluate the capability of a
rectal probe scintigraphy device (ProxiScanTM) to detect PSMA specific radiopharmaceutical
agent (ProstaScintÂ®; as a surrogate marker for prostate cancer) in patients who have
undergone a radical prostatectomy for their disease, patients with multiple negative
prostate biopsies and patients with known primary prostate cancer. Developed by Hybridyne
Imaging Technologies, Inc. ProxiScanTM is a small cadmium zinc telluride (CST)-based compact
gamma camera. It is the same size as a trans-rectal ultrasound (TRUS), currently used for
prostate biopsy guidance. Men with multiple positive biopsies will be considered controls.
Prostate cancer sextant biopsy histology results will be correlated with ProxiScanTM, TRUS,
MRI and SPECT/CT. The investigators hypothesize that it will be safe and feasible to utilize
a rectal probe scintigraphy (ProxiScanTM) to detect PSMA specific ProstaScintÂ®, thus
identifying and localizing the tumour sites within the prostate and surrounding areas.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society